Conversely, studies have revealed that the inhibition of S100A9 holds pivotal therapeutic significance in a plethora of CVD, encompassing atherosclerosis, MI, PAH, PAD, cardiomyopathy, and myocarditis. Here, S100A9 is linked to myocardial infarction.